

Disclaimer

This English translation is prepared by Marketing Authorization Holder.

The Japanese language package insert is the official document, and this translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version prevails.

The provider of this translation shall not be responsible for any damage that may be attributed to the use of the translation.

This translation shall not be reproduced, reprinted or used for profit.

Since this translation is prepared in July 2025 based on the Japanese text current at that time, the translation may not reflect the latest information, due to continuous revision of package inserts.

The latest Japanese text is available on PMDA website.

# Kracie

Oct 2023 (1st version)

Standard Commodity Classification No. of Japan	
875200	
Approval No.	15400AMZ01251000
Date of Initial Marketing in Japan	Sep 1981

Kampo product

## Uchida's HachimiganM Pills

Storage : Store at room temperature  
Shelf Life : 5 years

EK-700

### 3. COMPOSITION AND PRODUCT DESCRIPTION

#### 3.1 Composition

Brand name	Uchida's Hachimigan M Pills
Active ingredients	The daily dose of this product, 6.154g (equivalent to 60 pills; dried finished weight: 6 g), contains 5.128 g of powdered crude drugs blended in the following proportions.
	JP Rehmannia Root 8 g
	JP Cornus Fruit 4 g
	JP Dioscorea Rhizome 4 g
	JP Alisma Tuber 3 g
	JP Poria Sclerotium 3 g
	JP Moutan Bark 3 g
	JP Cinnamon Bark 1 g
JP Processed Aconite Root 2 1 g	
Inactive ingredients	JP Honey

(JP: The Japanese Pharmacopoeia)

#### 3.2 Product Description

Dosage form	Pills
Color	Black-brown
Odor	Characteristic odor
Taste	Slightly sweet
ID code	EK-700

### 4. INDICATIONS

The following symptoms in patients who are easily fatigued, with cold limbs, have decreased urine output or polyuria, and dry mouth:

Leg pain, low back pain, numbness, blurred vision in the elderly, itching, dysuria, polyuria, swelling

### 6. DOSAGE AND ADMINISTRATION

The usual dose is 2 g (20 pills).

For adults, administer orally three times daily, before or between meals.

The dosage may be adjusted according to the patient's symptoms.

### 8. IMPORTANT PRECAUTIONS

**8.1** When this product is used, the patient's "SHO" (constitution/symptoms) should be taken into consideration. The patient's progress should be carefully monitored, and if no improvement in symptoms or findings is observed, continuous administration should be avoided.

**8.2** When this product is used in combination with other Kampo products, etc., attention should be paid to the duplication of the contained crude drugs. Special attention should be paid to concomitant use with preparations containing Processed Aconite Root.

### 9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS

#### 9.1 Patients with Complication or History of Diseases, etc.

##### 9.1.1 Patients with good physical strength

Adverse reactions are likely to occur, and the symptoms may be aggravated.

#### 9.1.2 Patients who are sensitive to heat, have severe hot flushes, and red face

Palpitation, hot flushes, numbness of the tongue, nausea, etc. may occur.

#### 9.1.3 Patients with an extremely weak gastrointestinal tract

Anorexia, epigastric distress, nausea, vomiting, abdominal pain, diarrhea, constipation, etc. may occur.

#### 9.1.4 Patients with anorexia, nausea, or vomiting

These symptoms may be aggravated.

#### 9.5 Pregnant Women

It is not recommended to administer this product to pregnant women or women who may possibly be pregnant. Moutan Bark contained in this product may cause premature birth or miscarriage, and adverse reactions of Powdered Processed Aconite Root are likely to occur.

#### 9.6 Breast-feeding Women

Considering the therapeutic benefits and the benefits of breastfeeding, continuation or discontinuation of breastfeeding should be considered.

#### 9.8 Geriatric Use

Since the physiological functions are generally decreased in elderly patients, careful supervision is recommended; measures such as reducing the dose may be considered.

### 11. ADVERSE REACTIONS

The following adverse reactions may occur. Patients should be carefully monitored, and if any abnormalities are observed, appropriate measures such as discontinuation of administration should be taken.

#### 11.2 Other Adverse Reactions

	Frequency unknown
Hypersensitivity	Rash, Redness, Pruritus, etc.
Liver	Hepatic function abnormal (increases in AST, ALT, T-Bil, etc.)
Gastrointestinal	Anorexia, Epigastric distress, Nausea, Vomiting, Abdominal pain, Diarrhea, Constipation, etc.
Other	Palpitation, Hot flushes, Numbness of the tongue, etc.

### 20. PRECAUTIONS FOR HANDLING

**20.1** To maintain the quality of the product, avoid moisture as much as possible and store in a cool place, away from direct sunlight.

**20.2** Avoid moisture, especially after opening, and handle with care.

**20.3** Since this product is made from crude drugs, the color of the product may vary.

### 22. PACKAGING

840 pills(20 × 42 packets ) [pouch]

5040 pills(20 × 252 packets ) [pouch]

5000 pills [bottle, with desiccant enclosed]

**26. MARKETING AUTHORIZATION HOLDER, etc.**

**26.1 Manufactured and Distributed by:**

**UCHIDA WAKANYAKU Ltd.**

11-10 Higashinippori 5-Chome, Arakawa-ku, Tokyo  
116-0014, Japan

**26.2 Distributed by:**

**Kracie Pharmaceutical, Ltd.**

20-20, Kaigan 3-Chome, Minato-ku, Tokyo 108-8080, Japan